A Cost-Utility Analysis of Lisdexamfetamine Versus Atomoxetine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Inadequate Response to Methylphenidate

[1] Polanczyk G(2007)The worldwide prevalence of ADHD: a systematic review and meta-regression analysis Am J Psychiatry. 164 942-948

[2] de Lima MS(2009)Amfetamine for attention deficit hyperactivity disorder in people with intellectual disabilities Cochrane Database Syst Rev. 1 CD007009-i7

[3] Horta BL(2005)The effect of ADHD on the life of an individual, their family, and community from preschool to adult life Arch Dis Child. 90 i2-105

[4] Biederman J(2010)The quality of life of children with attention deficit/hyperactivity disorder: a systematic review Eur Child Adolesc Psychiatry. 19 83-1002

[5] Rohde LA(2012)Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States J Am Acad Child Adolesc Psychiatry. 51 990-598

[6] Thomson A(2014)Economic impact of childhood/adolescent ADHD in a European setting: the Netherlands as a reference case Eur Child Adolesc Psychiatry. 23 587-129

[7] Maltezos S(2014)Attention-deficit/hyperactivity disorder with inadequate response to stimulants: approaches to management CNS Drugs. 28 121-495

[8] Paliokosta E(2006)Long-acting medications for the hyperkinetic disorders: a systematic review and European treatment guideline Eur Child Adolesc Psychiatry. 15 476-388

[9] Xenitidis K(2008)A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom Value Health. 11 376-1218

[10] Harpin V(2013)European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder Eur Neuropsychopharmacol. 23 1208-405

[1] Polanczyk G(2007)The worldwide prevalence of ADHD: a systematic review and meta-regression analysis Am J Psychiatry. 164 942-948

[2] de Lima MS(2009)Amfetamine for attention deficit hyperactivity disorder in people with intellectual disabilities Cochrane Database Syst Rev. 1 CD007009-i7

[3] Horta BL(2005)The effect of ADHD on the life of an individual, their family, and community from preschool to adult life Arch Dis Child. 90 i2-105

[4] Biederman J(2010)The quality of life of children with attention deficit/hyperactivity disorder: a systematic review Eur Child Adolesc Psychiatry. 19 83-1002

[5] Rohde LA(2012)Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States J Am Acad Child Adolesc Psychiatry. 51 990-598

[6] Thomson A(2014)Economic impact of childhood/adolescent ADHD in a European setting: the Netherlands as a reference case Eur Child Adolesc Psychiatry. 23 587-129

[7] Maltezos S(2014)Attention-deficit/hyperactivity disorder with inadequate response to stimulants: approaches to management CNS Drugs. 28 121-495

[8] Paliokosta E(2006)Long-acting medications for the hyperkinetic disorders: a systematic review and European treatment guideline Eur Child Adolesc Psychiatry. 15 476-388

[9] Xenitidis K(2008)A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom Value Health. 11 376-1218

[10] Harpin V(2013)European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder Eur Neuropsychopharmacol. 23 1208-405